SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMPs decline and persistent losses are driving discussion, with many traders calling the politically branded memecoin a scam or rug pull and lamenting their holdings. Some supporters expect a rebound or short squeeze, but those views are speculative.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins sharp selloff and break below a key psychological support level dominate discussion, with traders pointing to heavy selling and leveraged long liquidations. The community is split between expecting further losses and viewing the dip as a potential bear trap or buying opportunity.

Blacksky Technology, Inc. is a space-based intelligence company, which engages in the business of delivering real-time imagery, analytics, and high-frequency monitoring of most critical and strategic locations, economic assets, and events. The firm is also involved in providing geospatial intelligence, imagery and related data analytic products and services, and mission systems that include the development, integration, and operation of satellite and ground systems to government and commercial customers. The company was founded in 2014 and is headquartered in Herndon, VA.

BlackSky Technology Inc - Ordinary Shares - Class A

BlackSkys expanded seven-figure Gen-3 Assured contract with an international defense partner is drawing attention, with traders viewing the customer expansion as positive but questioning why the stocks reaction has been muted. Some also point to Rocket Lab as a potential launch partner, though that is speculation.

United States Natural Gas Fund LP. - United States Natural Gas Fund

United States Natural Gas Fund, LP

UNG is drawing attention as natural gas weakness and fresh 52-week lows are attributed by bearish traders to warmer weather expectations and surplus inventories. Some investors are buying the dip or positioning for winter demand, but the community remains divided on whether a seasonal rebound will materialize.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

Bitcoins sharp swings and reported leveraged-position liquidations dominate the discussion, with bearish traders warning of further downside while bulls point to rebounds and renewed ETF demand. Macro conditions and crypto-regulation developments are also cited as potential influences, but sentiment remains divided.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Cantons institutional-adoption storyespecially DTCC tokenization plans and Visa joining the network as a super validatoris driving attention. Bulls see growing use for real-world asset infrastructure, while skeptics question whether that adoption will lift CCs price amid token issuance and unlocks.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

Northlands upgrade of C3.ai, citing its C3 Code platform for building agentic AI applications, is fueling bullish interest alongside discussion of a technical rebound and possible short covering. Skeptics counter that declining revenue and weak fundamentals make the rally difficult to trust.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is drawing attention for strong QNX momentum, including a record royalty backlog, its major Alloy Kore design win, and an Uber selection for a next-generation vehicle platform; the company also beat earnings expectations and raised its outlook. Bulls see these developments as evidence of growth in automotive software and physical AI, while skeptics question how quickly design wins will translate into revenue and point to volatile post-news trading.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Discussion is focused on claims that NEAR used DFINITY/ICP cryptographic technology, with traders speculating about possible legal action; the allegations are not established as fact. That debate is adding to an ongoing argument over ICPs weak price performance and whether its technology and adoption prospects can catch up with NEAR.

3M Co. is a technology company, which engages in manufacturing industrial, safety, and consumer products. It operates through the following segments: Safety and Industrial, Transportation and Electronics, Consumer, and Corporate. The Safety and Industrial segment consists of personal safety, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules. The Transportation and Electronics segment includes electronics, automotive and aerospace, commercial solutions, advanced materials, and transportation safety. The Consumer segment covers consumer healthcare, home care, home improvement, and stationery and office products, such as consumer bandages, braces, supports, respirators, cleaning products, retail abrasives, picture hanging, and consumer air quality solutions. The Corporate segment refers to special items and other corporate expenses. The company was founded by Henry S. Bryan, Hermon W. Cable, John Dwan, William A. McGonagle, and J. Danley Budd in 1902 and is headquartered in St. Paul, MN.

3M Co.

3Ms quarterly earnings beat and higher full-year outlook, alongside its expanded Amazon data-center partnership, are driving attention. Bulls see evidence of a turnaround and AI-infrastructure opportunity, while skeptics note Amazons purchases are not guaranteed under the warrant arrangement and are betting the news-driven gains may fade.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Reported Phase 3 results for Mercks Keytruda combination with Modernas personalized melanoma vaccine are driving attention: the treatment reduced the risk of recurrence or death, but the results fell short of some traders higher expectations. The community is split between viewing the data as a meaningful cancer-vaccine advance and a sell-the-news disappointment, with Merck shares under pressure alongside Moderna.

Merck CEO Plays Down Cost Concerns Over Intismeran — ‘We Don't See Cost As A Limit To Access’

Equity

In an interview with CNBC, Merck CEO Rob Davis said the company is confident it can deliver Intismeran at scale.


MRNA Tanks as Positive Phase III Cancer Therapy Data Fails to Impress

Moderna falls despite positive phase III cancer therapy data showing reduced melanoma recurrence and metastasis risks, as investors weigh elevated expectations.

MRNA Stock’s Vaccine Rally Cracks As Worst Week In 3 Months Looms — Analyst Calls It A ‘Do-Not-Trade’ Over Wild Swings 

Mizuho analyst Jared Holz said the vaccine data weren’t bad, but Wall Street’s expectations were too high.

MRNA Stock Plunges 18% After Leaked Melanoma Vaccine Data Misses High Hopes

Investors were awaiting full data from the late-stage trial of intismeran autogene plus Merck’s Keytruda at the European Society for Medical Oncology Congress on October 24.


Merck and Moderna Will Present Results From Landmark Phase 3 INTerpath-001 Trial for Intismeran Autogene Plus KEYTRUDA (pembrolizumab) at ESMO 2026 Presidential Symposium

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced detailed positive recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) results from the Phase 3 INTerpath-001 trial evaluating intismeran autogene...

Summit Expands Ivonescimab Development Into Biliary Tract Cancer

SMMT is advancing ivonescimab into BTC, launching a phase II/III study to compare its survival benefits with established immunotherapy regimens.

Earnings Preview: Merck (MRK) Q3 Earnings Expected to Decline

Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Merck (MRK) Laps the Stock Market: Here's Why

The latest trading day saw Merck (MRK) settling at $149.88, representing a +1.07% change from its previous close.

Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market

Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.   New York, NY – October 21, 2026 – Brain cancer remains one of the hardest cancers to treat, and researchers are under pressure to find therapies that do more than slow the […]
The post Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market appeared first on Financial News Media.

Can BMY Navigate Generic Challenges Across Its Key Drug Portfolio?

Bristol Myers faces mounting generic competition across its legacy portfolio, while Eliquis delivers strong growth and Revlimid shows resilience amid pricing and market pressures.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Bullish Sentiment

<ul class="summary-bullets"><li>On Thursday, MRNA shares plunged more than 17% after Phase 3 trial data was leaked ahead of Saturday’s ESMO presentation.</li><li>Intismeran, combined with Keytruda, reduced the risk of melanoma recurrence or death by 58% after six months, compared with Keytruda alone.</li><li>Merck and Moderna anticipate potential approval of the drug in 2027.</li></ul>Merck (MRK) CEO Rob Davis expressed confidence in the commercial potential of the much-talked-about personalised cancer vaccine, Intismeran, playing down concerns that its complex manufacturing process could make the treatment too expensive for patients.His comments came after Citi <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-citi-questions-whether-melanoma-vaccine-s-benefit-justifies-individualized-tumor-harvesting-and-manufacturing/cZxy0EZRBxl">questioned</a> whether the vaccine’s clinical benefits justify the cost and complexity of production.In an interview with CNBC on Friday, Davis credited Moderna’s mRNA technology and specialized manufacturing process for making personalized cancer vaccines commercially viable.“We think we will have very competitive costs, and we don’t see cost as a limit to access,” Davis said.At the time of writing, <a class="mention" data-mention="$MRK" data-symbol-id="MRK" href="https://stocktwits.com/symbol/MRK" target="_blank">MRK shares</a> were down 2.2% while <a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> traded 0.1% lower.<h2 class="st-heading-2">Davis ‘Very Confident’ On Delivering Vaccine On Scale</h2>Intismeran is a personalized cancer vaccine being developed using Moderna’s mRNA technology. The two companies are jointly developing the treatment, which is being tested alongside Merck’s blockbuster cancer drug Keytruda. Unlike traditional vaccines, Intismeran is customized using genetic mutations identified in each patient’s tumor.Davis said the process currently takes about six weeks, from analyzing a patient’s tumor to manufacturing the vaccine. “So it’s actually very efficient, and one, we feel very confident, we can deliver on scale,” Davis added.Intismeran, Keytruda Reduced Risk Of Melanoma Recurrence Or Death By 58% After Six MonthsOn Thursday, MRNA shares plunged more than 17% after Phase 3 trial data, which was leaked ahead of Saturday’s ESMO presentation, fell short of investors’ expectations, triggering what analysts described as a “sell-the-news” reaction.Merck and Moderna subsequently <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://feeds.issuerdirect.com/news-release.html?newsid=8277620888059962">released</a> the official findings, with Intismeran, combined with Keytruda, reducing the risk of cancer returning or death by 42% compared with Keytruda alone. The results were even better after six months, with the combination reducing the risk of melanoma recurrence or death by 58%, compared with Keytruda alone.“What’s not appreciated is because this is an immunisation, much like you would get if you got a vaccine, you really need to look at the six-month data. That’s the time that allows your body to fully mount an immune response at six months, and it has reduced the risk of recurrence or death by 58%. So this is meaningful if you’re a patient,” Davis said.<h2 class="st-heading-2">Potential Approval in 2027</h2>Davis said Merck and Moderna are moving quickly to seek regulatory approval for Intismeran, with hopes of filing an application before the end of 2026."We’re working as fast as we can right now to get the file in,” Davis said, adding that the companies anticipate potential approval sometime in 2027.<h2 class="st-heading-2">Retail’s Take On MRNA, MRK</h2>Retail sentiment surrounding MRK on Stocktwits remained ‘bullish’ over the past 24 hours while sentiment for MRNA turned ‘neutral’ from ‘bearish’ over the same period.Chatter largely centered on the data, which left some users disappointed.<stembedurl>https://stocktwits.com/DataTraders/message/667200038</stembedurl><stembedurl>https://stocktwits.com/Adrianople117/message/667206821</stembedurl>While MRK shares have climbed 36% so far this year, MRNA continues to be among the top biotech gainers, with a 550% surge.Also read:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/be-stock-extends-selloff-after-q3-print-but-morgan-stanley-sees-a-production-ramp-ahead/cZxyKioRBxn">BE Stock Extends Selloff After Q3 Print, But Morgan Stanley Sees A Production Ramp Ahead</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A syringe and some pills are in front of the logo of Merck pharmaceutical company. (Photo by Nikos Pekiaridis/NurPhoto via Getty Images)

In an interview with CNBC, Merck CEO Rob Davis said the company is confident it can deliver Intismeran at scale.

Moderna Inc

SPDR S&P Biotech ETF

Track MRK stock price, charts, news and real-time market activity on Stocktwits. Join the MRK message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around Merck & Co Inc stock.

MRK Stock Price Today - Merck & Co Inc News, Charts, Retail Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$145.27
Prev Close	$147.24
Open	$145.02
Dividend Yield	3.12%
50-Day Moving Average	$146.64
Beta	0.28
Avg. Volume	9.74M
PE Ratio	116.11

52-Week High	$156.92
52-Week Low	$82.01
Market Capitalization	$358.41B
EPS (Annual)	$7.28
Price to Book	8.55
Revenue Per Employee	$865,680.00

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

MRK Fundamentals